We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$9.32B
AUM Growth
+$2.47B
Cap. Flow
+$393M
Cap. Flow %
4.22%
Top 10 Hldgs %
43.12%
Holding
161
New
36
Increased
24
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$348M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$229M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$100M
4
CCCC icon
C4 Therapeutics
CCCC
+$91.6M
5
KRON
Kronos Bio
KRON
+$87.2M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$190M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$112M
3
IMMU
Immunomedics Inc
IMMU
+$77.6M
4
BPMC
Blueprint Medicines
BPMC
+$61.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 85.2%
2 Financials 0.33%
3 Industrials 0.29%
4 Materials 0.22%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
26
DELISTED
Albireo Pharma Inc
ALBO
$88.5M 0.95%
2,360,139
– –
QTNT
27
DELISTED
Quotient Limited Ordinary Shares
QTNT
$84.4M 0.91%
405,020
– –
KRON
28
DELISTED
Kronos Bio
KRON
$83M 0.89%
+2,780,097
New +$87.2M
ARWR icon
29
Arrowhead Research
ARWR
$12.1B
$82.2M 0.88%
+1,070,814
New +$68.5M
SLDB icon
30
Solid Biosciences
SLDB
$792M
$81.9M 0.88%
720,257
+270,270
+60% +$17.1M
CHRS icon
31
Coherus Oncology
CHRS
$217M
$81.2M 0.87%
4,671,836
+1,035,351
+28% +$18.4M
CERE
32
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$75.3M 0.81%
+4,544,062
New +$59M
PRVB
33
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$71.6M 0.77%
4,224,389
-41,322
-1% -$619K
KDMN
34
DELISTED
Kadmon Holdings, Inc.
KDMN
$65.2M 0.7%
15,711,334
– –
IMVT icon
35
Immunovant
IMVT
$7.93B
$64.7M 0.69%
1,400,000
– –
ONCR
36
DELISTED
Oncorus, Inc.
ONCR
$64.3M 0.69%
+1,989,987
New +$46.1M
NARI
37
DELISTED
Inari Medical, Inc. Common Stock
NARI
$58.4M 0.63%
668,500
-180,000
-21% -$12.7M
ZNTL icon
38
Zentalis Pharmaceuticals
ZNTL
$332M
$54.5M 0.59%
1,050,003
– –
PMVP icon
39
PMV Pharmaceuticals
PMVP
$57.1M
$54.5M 0.58%
885,556
+280,000
+46% +$11M
TARS icon
40
Tarsus Pharmaceuticals
TARS
$2.55B
$53.6M 0.58%
+1,296,416
New +$36.9M
ADPT icon
41
Adaptive Biotechnologies
ADPT
$3.61B
$53.5M 0.57%
904,854
+74,854
+9% +$3.86M
CRNX icon
42
Crinetics Pharmaceuticals
CRNX
$8.88B
$51.6M 0.55%
3,659,381
– –
UROV
43
DELISTED
Urovant Sciences Ltd.
UROV
$50.3M 0.54%
3,116,831
+750,000
+32% +$9.3M
CMPS
44
Compass Pathways
CMPS
$1.47B
$49.9M 0.54%
1,047,404
– –
AGRX
45
DELISTED
Agile Therapeutics
AGRX
$45.7M 0.49%
7,960
– –
ARNA
46
DELISTED
Arena Pharmaceuticals Inc
ARNA
$44.2M 0.47%
575,007
-50,122
-8% -$3.76M
FMTX
47
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$43.6M 0.47%
1,250,000
– –
ALDX icon
48
Aldeyra Therapeutics
ALDX
$97.1M
$43.1M 0.46%
6,285,458
– –
STOK icon
49
Stoke Therapeutics
STOK
$1.84B
$41.6M 0.45%
671,978
– –
COLL icon
50
Collegium Pharmaceutical
COLL
$1.18B
$41.2M 0.44%
2,058,068
– –
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Perceptive Advisors held 161 positions worth $9.32B, up 36% from $6.85B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors deployed $393M of net new capital in Q4 2020, opening 36 new positions and adding to 24 existing holdings. Its largest new stake was Invitae Corporation: 7,284,466 shares worth $305M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $36.5M trimmed.

  • Perceptive Advisors's largest Q4 2020 buy was Invitae Corporation: 7,284,466 shares worth $305M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $55.8M increase.
  • Perceptive Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $36.5M.
  • Perceptive Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $190M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $9.32B portfolio in Q4 2020.
  • Perceptive Advisors opened 36 new positions and closed 22 in Q4 2020.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $9.32B.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.